SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tablet
Phase 2UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Gout and Hyperuricemia
Conditions
Primary Gout and Hyperuricemia
Trial Timeline
Sep 15, 2022 → Sep 20, 2023
NCT ID
NCT05513976About SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tablet
SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tablet is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Primary Gout and Hyperuricemia. The current trial status is unknown. This product is registered under clinical trial identifier NCT05513976. Target conditions include Primary Gout and Hyperuricemia.
What happened to similar drugs?
20 of 20 similar drugs in Primary Gout and Hyperuricemia were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05513976 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Primary Gout and Hyperuricemia